Compare KPTI & SKLZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KPTI | SKLZ |
|---|---|---|
| Founded | 2008 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 94.6M | 78.0M |
| IPO Year | 2013 | N/A |
| Metric | KPTI | SKLZ |
|---|---|---|
| Price | $7.23 | $4.41 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 1 |
| Target Price | ★ $22.17 | $14.00 |
| AVG Volume (30 Days) | ★ 260.1K | 77.6K |
| Earning Date | 02-18-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $142,530,000.00 | $92,256,000.00 |
| Revenue This Year | $3.82 | $13.33 |
| Revenue Next Year | N/A | $12.68 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.51 | $3.54 |
| 52 Week High | $12.45 | $9.11 |
| Indicator | KPTI | SKLZ |
|---|---|---|
| Relative Strength Index (RSI) | 60.53 | 29.16 |
| Support Level | $7.12 | $4.23 |
| Resistance Level | $7.52 | $4.64 |
| Average True Range (ATR) | 0.48 | 0.26 |
| MACD | 0.04 | -0.04 |
| Stochastic Oscillator | 71.64 | 12.00 |
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
Skillz Inc is a two-sided mobile gaming platform that connects developers with competitive players. The company's reportable business segments are: the Skillz segment and the Aarki segment. Skillz segment's highlights include Monetize Through Competitions, Player Matching, Cross-Platform Support, Comprehensive Analytics, and Focus on Game Development. Aarki is an artificial intelligence company that delivers advertising solutions. Some of the games available on its platform are Dominoes Gold, Blackout Bingo, 21 Blitz, and Solitaire Cube among others. The majority of its revenue is generated from the Skillz segment. Geographically, the company derives its key revenue from the United States and the rest from Israel, China, Malta, and other countries.